Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Call Scheduled for Friday, November 3, 2017 at 10:30 a.m. ET
NEW YORK, Oct. 24, 2017 -- AIT Therapeutics Inc. (OTC:AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), will report financial results for the three- and nine-months ended September 30, 2017 and host a conference call and webcast at 10:30am Eastern Time on Friday, November 3.
Conference Call & Webcast
| Friday, November 3rd @ 10:30am Eastern Time | |
| Domestic: | 888-438-5449 |
| International: | 719-325-2450 |
| Passcode: | 1870535 |
| Webcast: | http://public.viavid.com/index.php?id=126768 |
| Replays available through November 17: | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 1870535 |
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]
Bob Yedid
LifeSci Advisors, LLC
[email protected]
(646) 597 6989
